CN105188702B - 使用双嘧达莫的用于治疗眼睛疾病的组合物 - Google Patents
使用双嘧达莫的用于治疗眼睛疾病的组合物 Download PDFInfo
- Publication number
- CN105188702B CN105188702B CN201480016302.6A CN201480016302A CN105188702B CN 105188702 B CN105188702 B CN 105188702B CN 201480016302 A CN201480016302 A CN 201480016302A CN 105188702 B CN105188702 B CN 105188702B
- Authority
- CN
- China
- Prior art keywords
- dipyridamole
- eye
- disease
- eyes
- drop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229960002768 dipyridamole Drugs 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 208000022873 Ocular disease Diseases 0.000 title abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 30
- 206010013774 Dry eye Diseases 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 206010029113 Neovascularisation Diseases 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 206010018473 Glycosuria Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000006196 drop Substances 0.000 description 29
- 210000001508 eye Anatomy 0.000 description 27
- 238000009472 formulation Methods 0.000 description 24
- 210000004087 cornea Anatomy 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 11
- 231100000397 ulcer Toxicity 0.000 description 11
- 208000030533 eye disease Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 206010002091 Anaesthesia Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 201000004768 pinguecula Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 229940012356 eye drops Drugs 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010023332 keratitis Diseases 0.000 description 5
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 206010069732 neurotrophic keratopathy Diseases 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 201000002287 Keratoconus Diseases 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 241000219095 Vitis Species 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 201000005111 ocular hyperemia Diseases 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001745 uvea Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010010984 Corneal abrasion Diseases 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 206010022941 Iridocyclitis Diseases 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000000222 Viral Eye Infections Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 201000004612 anterior uveitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 210000003683 corneal stroma Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000016134 Conjunctival disease Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000014260 Fungal keratitis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 206010034944 Photokeratitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000320 anti-stroke effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 208000024754 bloodshot eye Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL225179A IL225179A (en) | 2013-03-12 | 2013-03-12 | Compounds for use in ocular disorders using dipyridamole |
| IL225179 | 2013-03-12 | ||
| PCT/IB2014/059645 WO2014141079A1 (en) | 2013-03-12 | 2014-03-11 | Compositions for use in treating eye disorders using dipyridamole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105188702A CN105188702A (zh) | 2015-12-23 |
| CN105188702B true CN105188702B (zh) | 2019-03-26 |
Family
ID=48916407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480016302.6A Expired - Fee Related CN105188702B (zh) | 2013-03-12 | 2014-03-11 | 使用双嘧达莫的用于治疗眼睛疾病的组合物 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2968328A4 (ko) |
| JP (1) | JP6820658B2 (ko) |
| KR (2) | KR20210010638A (ko) |
| CN (1) | CN105188702B (ko) |
| AU (1) | AU2014229371B2 (ko) |
| BR (1) | BR112015022084A2 (ko) |
| CA (1) | CA2905594A1 (ko) |
| CL (1) | CL2015002627A1 (ko) |
| EA (1) | EA035966B1 (ko) |
| IL (1) | IL225179A (ko) |
| MX (1) | MX2015012716A (ko) |
| MY (1) | MY182591A (ko) |
| SG (2) | SG10201706937UA (ko) |
| WO (1) | WO2014141079A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6925272B2 (ja) * | 2015-01-28 | 2021-08-25 | リアルイン ライフ サイエンス リミテッド | ＰＰＡＲγ発現および核転座を促進する化合物およびそれの治療的使用 |
| US20180092776A1 (en) | 2016-09-30 | 2018-04-05 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
| WO2021001806A1 (en) | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Stable dipyridamole formulations with reduced impurities |
| WO2021001805A1 (en) | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Stable dipyridamole formulations and their methods of preparation |
| WO2024125322A1 (zh) * | 2022-12-16 | 2024-06-20 | 智泽童康(广州)生物科技有限公司 | 防治过敏性和/或炎症性疾病的双嘧达莫及其制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07258084A (ja) * | 1994-03-17 | 1995-10-09 | Rohto Pharmaceut Co Ltd | ジピリダモールを必須成分とする眼圧降下剤 |
| US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| EP2218442A1 (en) * | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
| WO2010056710A1 (en) * | 2008-11-11 | 2010-05-20 | Biovista, Inc. | Compositions and methods for treating eye diseases |
| EP2363126A1 (en) * | 2010-03-04 | 2011-09-07 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation |
-
2013
- 2013-03-12 IL IL225179A patent/IL225179A/en active IP Right Grant
-
2014
- 2014-03-11 MY MYPI2015002196A patent/MY182591A/en unknown
- 2014-03-11 CN CN201480016302.6A patent/CN105188702B/zh not_active Expired - Fee Related
- 2014-03-11 BR BR112015022084A patent/BR112015022084A2/pt active Search and Examination
- 2014-03-11 KR KR1020217001495A patent/KR20210010638A/ko not_active Application Discontinuation
- 2014-03-11 JP JP2015562486A patent/JP6820658B2/ja not_active Expired - Fee Related
- 2014-03-11 SG SG10201706937UA patent/SG10201706937UA/en unknown
- 2014-03-11 SG SG11201507092QA patent/SG11201507092QA/en unknown
- 2014-03-11 EA EA201591653A patent/EA035966B1/ru unknown
- 2014-03-11 EP EP14764673.1A patent/EP2968328A4/en not_active Withdrawn
- 2014-03-11 CA CA2905594A patent/CA2905594A1/en not_active Abandoned
- 2014-03-11 KR KR1020157027571A patent/KR20150126021A/ko not_active IP Right Cessation
- 2014-03-11 AU AU2014229371A patent/AU2014229371B2/en not_active Ceased
- 2014-03-11 MX MX2015012716A patent/MX2015012716A/es unknown
- 2014-03-11 WO PCT/IB2014/059645 patent/WO2014141079A1/en active Application Filing
-
2015
- 2015-09-11 CL CL2015002627A patent/CL2015002627A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015022084A2 (pt) | 2017-07-18 |
| MX2015012716A (es) | 2016-07-06 |
| JP6820658B2 (ja) | 2021-01-27 |
| EA201591653A1 (ru) | 2017-05-31 |
| AU2014229371A1 (en) | 2015-10-29 |
| EP2968328A4 (en) | 2016-11-23 |
| SG10201706937UA (en) | 2017-09-28 |
| CN105188702A (zh) | 2015-12-23 |
| WO2014141079A1 (en) | 2014-09-18 |
| IL225179A (en) | 2017-01-31 |
| KR20210010638A (ko) | 2021-01-27 |
| CL2015002627A1 (es) | 2016-03-11 |
| JP2016514123A (ja) | 2016-05-19 |
| CA2905594A1 (en) | 2014-09-18 |
| AU2014229371B2 (en) | 2018-05-10 |
| KR20150126021A (ko) | 2015-11-10 |
| IL225179A0 (en) | 2013-06-27 |
| MY182591A (en) | 2021-01-26 |
| SG11201507092QA (en) | 2015-10-29 |
| EA035966B1 (ru) | 2020-09-07 |
| EP2968328A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5583310B2 (ja) | 眼球の症状の予防及び治療のための眼科用製剤 | |
| CN105188702B (zh) | 使用双嘧达莫的用于治疗眼睛疾病的组合物 | |
| US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
| Simone et al. | Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery | |
| EP3808352A1 (en) | Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins | |
| Chelnis et al. | Urrets-Zavalia syndrome following goniotomy in a child | |
| JP2005501100A (ja) | 視力を改善する生理学的方法 | |
| US10279046B2 (en) | Eye drop composition for treating ocular inflammatory disease and preparation method therefor | |
| JPH10158171A (ja) | ビタミンｄ化合物を配合した眼内投与剤 | |
| US9254289B2 (en) | Methods for treating eye disorders using dipyridamole | |
| Sayed et al. | Neurotrophic keratopathy after slow coagulation transscleral cyclophotocoagulation | |
| RU2485939C1 (ru) | Офтальмологический препарат в виде глазных капель, содержащий дисульфирам и таурин | |
| AlDarrab et al. | Spontaneous glaucoma drainage device extrusion after early postoperative orbital cellulitis–Case report and literature review | |
| Hyung et al. | Management of chronic hypotony following trabeculectomy with mitomycin C. | |
| Kozomara et al. | Simultaneous bilateral implantation of ex-press glaucoma shunt for secondary glaucoma treatment due to axenfeld-rieger syndrome: a case report | |
| RU2310452C1 (ru) | Способ иммунореабилитации при лечении воспалений переднего отрезка глаза | |
| Trofimova | Preventive ophthalmology: What anti-aging specialists should know about eye diseases? | |
| WO2021163253A1 (en) | Progesterone combinations | |
| Mitra | Translating novel drug delivery techniques to ophthalmic products-unique opportunity for collaboration between academia and pharmaceutical industry | |
| JPH07112942A (ja) | 黄斑円孔及び網膜裂孔の治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170904 Address after: Rehovot Applicant after: O. D. Okaradis Caffrey Co. Address before: New jersey, USA Applicant before: Raymond Leaf |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190326 |